Any other use, including for any commercial purposes, is strictly prohibited without our express prior written consent. You may use and the contents contained in solely for your own individual non-commercial and informational purposes only. Liable for your own investment decisions and agree to the Users should not base their investment decision upon. (RAPT) are surging over 50 on Monday morning after the company reported positive topline results from early stage study for. is a research service that provides financial data and technical analysis of publicly traded stocks.Īll users should speak with their financial advisor before buying or selling any securities. (RTTNews) - Shares of RAPT Therapeutics, Inc. There can be a variety of reasons for this, but in general it can be considered as a negative signal. In general the insiders are selling more stocks than they buy. The last trade was done 15 days ago by Ho William who sold 3 thousand shares. This suggests a possible upside of 104.4 from the stock's current price. On average, they expect RAPT Therapeutics' stock price to reach 60.29 in the next twelve months. Their forecasts range from 49.00 to 72.00. In the last 100 trades there were 881.06 thousand shares bought and 3.33 million shares sold. 7 equities research analysts have issued 1-year price objectives for RAPT Therapeutics' stock. Insiders are very negative selling more shares than they are buying in RAPT Therapeutics, Inc. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate. We therefore hold a negative evaluation of this stock.
holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We hold an negative evaluation for this stock. Some stocks may fall long and hard while being oversold on RSI, but stocks that are heavily oversold on RSI often pose good re-bounce chance and played well it can be a buy candidate. For the last week, the stock has had a daily average volatility of 11.03%. During the last day, the stock moved $2.15 between high and low, or 10.85%. This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days. This may be an early warning and the stock should be followed more closely. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Further fall is indicated until a new bottom pivot has been found. A sell signal was issued from a pivot top point on Thursday, January 06, 2022, and so far it has fallen -49.95%. A break-up above any of these levels will issue buy signals. On corrections up, there will be some resistance from the lines at $21.87 and $31.36. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Robbins’ extensive experience in the biopharmaceutical industry, her industry expertise and financial knowledge provide her with the qualifications and skills to serve as a director of our company.There are few to no technical positive signals at the moment. in Business Administration from the Haas School of Business at the University of California, Berkeley. from The Medical College of Pennsylvania and a B.S. Robbins completed her residency in Anesthesiology at Johns Hopkins University School of Medicine, her internship in Internal Medicine at the University of Pennsylvania School of Medicine, and received her fellowship training in Pain Medicine from John Hopkins University School of Medicine. Robbins has also served on the faculty at Stanford University School of Medicine in the Department of Anesthesia, Perioperative Care, and Pain Medicine since 2004. Robbins has also served as an independent consultant to venture investors in company formation and translational biology. She has served as President and CEO of Blade Therapeutics since August 2016 (and previously held the title of Interim CEO from May 2015 to July 2016). serves as Independent Director of the Company.
0 kommentar(er)
